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ment of Medicine, University of California San Diego, San Diego, California, USAAcute kidney injury (AKI) is independently associated with new-onset chronic kidney disease (CKD),
end-stage kidney disease, cardiovascular disease, and all-cause mortality. However, only a minority of
patients receive follow-up care after an episode of AKI in the developing world, and the optimal strategies
to promote rehabilitation after AKI are ill-deﬁned. On this background, a working group of the 18th Acute
Dialysis Quality Initiative applied the consensus-building process informed by a PubMed review of
English-language articles to address questions related to rehabilitation after AKI. The consensus state-
ments propose that all patients should be offered follow-up within 3 months of an AKI episode, with more
intense follow-up (e.g., <1 month) considered based on patient risk factors, characteristics of the AKI
event, and the degree of kidney recovery. Patients should be monitored for renal and nonrenal events
post-AKI, and we suggest that the minimum level of monitoring consist of an assessment of kidney
function and proteinuria within 3 months of the AKI episode. Care should be individualized for higher risk
patients, particularly patients who are still dialysis dependent, to promote renal recovery. Although
evidence-based treatments for survivors of AKI are lacking and some outcomes may not be modiﬁable, we
recommend simple interventions such as lifestyle changes, medication reconciliation, blood pressure
control, and education, including the documentation of AKI in the patient’s medical record. In conclusion,
survivors of AKI represent a high-risk population, and these consensus statements should provide
clinicians with guidance on the care of patients after an episode of AKI.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A cute kidney injury (AKI) is a common complica-tion that affects as many as 20% of hospitalized
patients in both high- and lower middle–income
countries.1,2 Most of our current efforts for patients
with AKI are concentrated on the period when kidney
function is worsening. If the patient survives and
experiences what appears to be full or partial recovery
of kidney function, the physician typically “signs off,”
and no routine follow-up care is arranged.
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International Reports (2017) 2, 579–593persistent risk of adverse outcomes. Such complications
include de novo or accelerated chronic kidney disease
(CKD),3,4 end-stage renal disease (ESRD),5 hyperten-
sion,6 and cardiovascular disease.7,8 Although the na-
ture of the relation (causal vs. correlative) between AKI
and long-term outcomes remains a topic of debate,9,10
there is no doubt that, for many patients, an episode
of AKI heralds an ominous prognosis. AKI and CKD
may best be viewed as interrelated syndromes, with
AKI leading to CKD and CKD strongly predisposing to
the development of AKI (Figure 1).11 No matter the
relationship, patients who survive an episode of AKI
constitute a high-risk population who may beneﬁt from
more intensive post-AKI follow-up care.12
Despite their high-risk status, in the United States,
only 2 in 5 patients will have their serum creatinine579
Figure 1. Acute kidney injury (AKI) and chronic kidney disease (CKD)
as interrelated syndromes. AKI and CKD often form a continuum of
disease as opposed to separate entities. They share common risk
factors, with both AKI and CKD associated with adverse outcomes.
ESRD, end-stage renal disease
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than 1 in 6 patients will see a nephrologist within 90
days of an AKI episode.13,14 Even among patients
hospitalized for dialysis-requiring AKI who recover
sufﬁcient kidney function to no longer require
dialysis, <50% see a nephrologist within 1 year of
hospital discharge.15 Although observational studies
from high-income countries suggest that patients who
receive follow-up by a nephrologist after an episode of
AKI have improved outcomes compared with patients
who do not receive follow-up,15,16 little is known
about speciﬁc strategies to increase follow-up,
monitor, and promote recovery after an AKI episode.
Even less is known about how to tailor AKI follow-up
programs to the sociocultural, policy, ﬁnancial, and
medical circumstances in lower middle–income
countries.
On this background, the steering committee of the
18th Acute Dialysis Quality Initiative (ADQI) confer-
ence dedicated a work group with the task of consid-
ering elements of rehabilitation after an episode of AKI
in the developing world. More speciﬁcally, the work
group addressed 5 questions:
1. Which patients should be followed after an AKI
episode?
2. What are the outcomes for which patients should be
monitored after an AKI episode?
3. What are the components of patient-centered
monitoring after an AKI episode?
4. What management strategies are recommended after
an AKI episode?
5. What educational strategies are recommended after
an AKI episode?
Methods
This consensus meeting followed the established ADQI
process, as previously described.17 The broad objec-
tive of ADQI is to provide expert-based statements580and interpretation of current knowledge for use by
clinicians according to professional judgment as well
as identify evidence care gaps to establish research
priorities. The 18th ADQI Consensus Conference
focused on “Management of AKI in the Developing
World,” convening a diverse panel for a 2.5-day
meeting in Hyderabad, India, from September 27 to
30, 2016. The consensus-building process was
informed by pre-conference, conference, and post-
conference activities. Before the conference, the
work group searched PubMed for English-language
articles on rehabilitation strategies after an episode of
AKI. This search included both monitoring and man-
agement strategies to enhance recovery after AKI as
well as the epidemiology of AKI survivors. A pre-
conference series of e-mails involving work group
members was used to identify the current state of
knowledge and enable the formulation of key ques-
tions. At the in-person meeting, the work group
developed consensus statements through a series of
alternating breakout and plenary sessions. In each
breakout session, the work group reﬁned the key
questions, identiﬁed the supporting evidence, and
generated consensus statements. Work group members
presented the results for feedback to all ADQI par-
ticipants during the plenary sessions and then revised
the drafts based on the plenary comments until a ﬁnal
version was accepted. After the conference, this
summary report was generated, revised, and approved
by all members of the work group.
Results
Overview of Existing Literature on Rehabilitation
After AKI in the Developing World
We identiﬁed only 4 published reports of AKI
follow-up programs,12,18–21 2 of which were from lower
middle–income countries.20,21 However, these latter
experiences did not describe their patient selection
strategy, follow-up care models, or patterns of care
delivered to patients. Most studies on the epidemiology
of AKI in the developing world also end patient follow-
up within 30-days of the AKI episode.2,22–25 Therefore,
the work group based most of its recommendations on
long-term AKI follow-up data from the developed
world. Care was taken to adapt these consensus state-
ments to the sociocultural, policy, ﬁnancial, and med-
ical circumstances in lower middle–income countries.
Question 1: Which patients should be followed
after an AKI episode?
Consensus Statement
 Consensus Statement 1A: All patients should be
considered for follow-up after an episode of AKI
because multiple studies in the literature haveKidney International Reports (2017) 2, 579–593
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with adverse outcomes.
 Consensus Statement 1B: The intensity of patient
follow-up should be individualized based on patient
risk factors, characteristics of the AKI episode, and
the degree of kidney recovery (Figure 2).
 Consensus Statement 1C: Patients with preexisting
CKD are at high risk of adverse events after an
episode of AKI and therefore should be prioritized for
follow-up regardless of the degree of renal recovery.
The unanswered question is what threshold of AKI
warrants follow-up. A meta-analysis showed that the
risk of CKD increased in a graded manner with mild
AKI (adjusted hazard ratio [HR] 2.0, 95% conﬁdence
interval [CI] 1.4–2.8), moderate AKI (adjusted HR 3.3,
95% CI 1.7–6.2), and severe AKI (adjusted HR 28.2,
95% CI 21.1–37.5).26 Moreover, the association with
adverse events seems to be present even among pa-
tients with mild and rapidly reversible AKI who
recover with normal or nearly normal kidney func-
tion.4,27 These results reinforce that it is challenging for
clinicians to determine who remains at risk after an
episode of AKI.
Accordingly, we recommend that all patients with
AKI receive some level of follow-up care. The intensity
of follow-up care should be based on established risk
factors for adverse events, which can be divided into 3
groups (Figure 2):
 Patient-speciﬁc risk factors
 Characteristics of the AKI episode
 Degree of kidney recoveryPatient-Specific Risk 
Factors
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Figure 2. Determinants of adverse outcomes and higher intensity follow-
based on 3 categories: patient risk factors, characteristics of the AKI episo
feature within any of these 3 categories is sufﬁcient to designate the
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Kidney International Reports (2017) 2, 579–593Patient-Speciﬁc Risk Factors
Several studies have reported patient-speciﬁc predictors
for adverse events after an episode of AKI, which should
inform the intensity of follow-up required. Although
there are notable differences in methodology, case mix,
and outcome ascertainment, many of these studies
identiﬁed similar risk factors. These include older
age,4,20,21,28–30 higher comorbidity score,4,31 preexisting
hypertension or cardiovascular disease,4,20,31–33 dia-
betes,29,32,33 low serum albumin,28,33 and recurrent
AKI.34 One study combined several risk factors into a
prognostic score for stage 4 CKD, but its feasibility is
limited by the inclusion of serum albumin, a laboratory
parameter that may not be routinely measured in lower
middle–income countries.28
One risk factor that should prioritize patients for
follow-up is preexisting CKD. Proteinuria is a risk
factor for adverse outcomes after AKI, which is not
surprising given its strong association with CKD pro-
gression.35 However, preexisting proteinuria is absent
from many AKI studies, and post-AKI proteinuria has
been reported as an outcome rather than incorporated
into multivariable models of adverse post-AKI out-
comes. Thakar et al.34 found that preexisting protein-
uria was associated with a 3-fold increase in stage 4
CKD in patients with diabetes after AKI, and James
et al.36 reported increased rates of death, ESRD, and
doubling of serum creatinine across increasing levels of
proteinuria in their population-based study. Most
studies found that lower baseline kidney function
increased the risk of ESRD and death after an episode of
AKI.20,21,31,37 Pannu et al.37 found that the impact ofharacteriscs of the 
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glomerular ﬁltration rate (eGFR) decreased, and in
patients with a baseline eGFR <30 ml/min per 1.73 m2,
ESRD was most likely to develop after AKI (16.6% with
AKI vs. 7.9% without AKI).37 A lower eGFR is also a
risk factor for recurrent AKI.33 A few studies have
observed that patients with normal GFR before AKI
have a higher relative risk for the development of ESRD
compared with AKI patients who have a decreased
baseline GFR.3,5,36,38 However, there is an extremely
low probability of ESRD in patients without AKI or a
decreased baseline GFR, which leads to higher relative
risks even though the absolute risk of ESRD after AKI
is much higher in patients with preexisting CKD. This
observation was reinforced by Sawhney et al.,39 who
found that baseline kidney function was the strongest
predictor of long-term outcomes, with the effect of AKI
diminishing after 1 year.39 Regardless of the role that
AKI plays in CKD progression, an episode of AKI
provides clinicians with an opportunity to identify
patients with preexisting CKD and arrange follow-up
for this high-risk population.40
Characteristics of the AKI Episode
Patients may have de novo AKI, acute-on-chronic kid-
ney injury, or AKI with unknown previous kidney
history. In 2012, the Kidney Disease Improving Global
Outcomes (KDIGO) AKI work group proposed the term
acute kidney disease to help unify the established con-
cepts of AKI and CKD.41 ADQI 16 further deﬁned acute
kidney disease as the acute to subacute loss of kidney
function and/or damage from initiation or recognition
to patient and kidney outcomes up to 90 days
including recovery, recurrence, and/or progression
(Figure 3). An AKI event will usually be observed, but
this is not required to diagnose acute kidney disease.
For example, community-acquired AKI is particularly
common in the developing world, responsible for 50%
to 80% of AKI episodes with high accompanying
mortality.2,3 These episodes may not be observed, but
rather inferred by the persistence of kidney diseaseFigure 3. Acute kidney disease–chronic kidney disease continuum.
For those patients with preexisting kidney disease, AKI and AKD are
superimposed on the CKD state, and the new level of renal function
represents the updated degree of CKD. The x-axis depicts time in
days, with time 0 representing the onset of AKI/AKD. AKD, acute
kidney disease; AKI, acute kidney injury; CKD, chronic kidney
disease.
582beyond 7 days, especially when a baseline creatinine
value is unavailable. Such data reinforce that the in-
tensity of patient follow-up should be individualized
and need not meet strict deﬁnitions for AKI or CKD.
Beyond the severity of the AKI episode according to
KDIGO AKI staging, patients with AKI who require
dialysis and then recover to become dialysis indepen-
dent are at especially high risk for adverse events.3,5 In
1 study, the need for dialysis increased the likelihood
of progression to stage 4 CKD by 500-fold (>5000%).28
The duration of the AKI episode is also important.
Persistent AKI (deﬁned by KDIGO criteria) is charac-
terized by the continuance of AKI creatinine or urine
output criteria beyond 48 hours from onset. Two
studies in postoperative patients demonstrated that the
duration of persistent AKI is directly proportional to
long-term mortality. Relative to patients without AKI,
an episode of AKI lasting $7days increased the risk of
long-term mortality by a magnitude of 2 to 3 times.42,43
The etiology of the AKI episode may also inﬂuence the
intensity of follow-up. Acute tubular necrosis relative
to acute renal failure (as deﬁned using ICD-9 diagnosis
codes) is associated with 60% higher odds for
progression to stage 4 CKD,28,44 and hypotension,
shock, and sepsis are common causes of AKI in lower
middle–income countries.2 Paradoxically, diagnoses
associated with kidney recovery may also warrant
closer follow-up to administer disease-speciﬁc therapies
and to protect the kidney from further insults. Such
etiologies that are more common in the developing
world relative to the developed world include acute
interstitial nephritis, glomerulonephritis, nephrotoxin-
induced AKI, and postpartum AKI.2,23,24
Degree of Kidney Recovery
There is currently no standardized deﬁnition of
recovery, but ADQI 16 recently aligned a framework for
kidney recoverywith the KDIGO categories forAKI. One
of the main messages is that it is difﬁcult to know
whether kidney recovery is complete. For example,
diminished serum creatinine generation, loss of muscle
mass, changes in volume of distribution, and hyper-
ﬁltration may confound the assessment of functional
recovery.45–50 A recent study by Stoumpos et al.51
demonstrated that in patients with AKI-requiring dial-
ysis, CKD will develop in very few who recover to an
eGFR >60 ml/min per 1.73 m2 at 12 months.51
Conversely, an episode of AKI that does not return to
its preexisting baseline constitutes a high-risk event. A
retrospective study of 1500 cardiac surgery patients
found that for each 88 mmol/l increase in creatinine at
discharge, the HR for death was 1.9 (95% CI 1.5–2.3).29
Pannu et al.32 also found in their population-based study
that survivors of AKI who did not recover kidneyKidney International Reports (2017) 2, 579–593
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kidney outcomes than individuals who recovered to
within 25% of their baseline serum creatinine (adjusted
HR for mortality 1.3, 95% CI 1.1–1.4; adjusted HR for
kidney outcomes 4.1, 95% CI 3.4–5.0). The degree of
kidney recovery may be an even more important factor
in the developing world, as 1 study in critical care pa-
tients found that only 52% of lower middle–income
country patients recovered kidney function compared
with 72% of patients in developed countries.24 There-
fore, patients whose creatinine does not return to base-
line (including patients who still require dialysis) should
be prioritized for follow-up. Baseline creatinine values
may not be available in all patients due to limited re-
sources,23 and when available, differences in laboratory
assays and standardization may threaten their accuracy
and interpretation.25 When in doubt, a persistently
elevated creatinine level with no clear baseline should be
recognized as AKD and managed as a high-risk event.Special Considerations
Pediatric studies usually contain <100 patients,52 so it
is difﬁcult to generate models that identify de-
terminants of adverse events after AKI. For example,
Mammen et al.53 found an association between AKI
severity and CKD in their 126-patient study, but this
relationship did not reach statistical signiﬁcance. A
systematic review from Sub-Saharan Africa identiﬁed
22 studies in pediatric AKI patients, but only 5 re-
ported rates of long-term CKD that could not be further
analyzed due to inconsistent reporting.25 While we
await publication of the multicenter Assessment of
Worldwide AKI, Renal Angina, and Epidemiology
(AWARE) study, we recommend applying our
consensus statements to the pediatric population until
further evidence becomes available.
In resource-limited settings, it may be challenging to
provide follow-up care to all patients after an AKI
episode. One approach is to stratify barriers to care by
sociocultural, policy, ﬁnancial, and medical factors.54
Sociocultural barriers include health beliefs and cus-
toms of patients (e.g., use of traditional medicine), and
providers that may limit AKI follow-up care, such as
the practice of treating male patients at the expense of
female patients.25 Policy and ﬁnancial factors include
ﬁnancial constraints (patients and hospitals), health
insurance coverage, and physician availability (both
primary care and nephrologists) that may limit access
to care.25 Such issues are particularly relevant to
community-acquired AKI, which may occur in remote
settings. Medical factors include inconsistent clinical
practice guidelines and health care provider education/
awareness of AKI and its long-term consequences.23,55Kidney International Reports (2017) 2, 579–593However, several of these barriers also apply to
high-income countries. Certainly, there are opportu-
nity costs to targeting all survivors of AKI for follow-
up care. Ideally, a simple and practical risk score
would identify patients at high risk of CKD progression
and mortality post-AKI. These patients could then be
triaged for follow-up care based on local resources and
practices, accounting for the aforementioned barriers
that affect the developing world. Until such a score is
available and validated in both high- and low-resource
settings, we recommend prioritizing patients for
follow-up similarly in both high-income and lower
middle–income countries.Question 2: What are the outcomes for which
patients should be monitored after an AKI
episode?
Consensus Statement
 Consensus Statement 2A: Because AKI is associated
with adverse kidney events, patients should be
monitored for de novo CKD, CKD progression, ESRD,
and further AKI episodes.
 Consensus Statement 2B: Patients should be monitored
for several nonrenal sequelae after an AKI episode,
including new-onset hypertension, cardiovascular
disease, all-cause hospital readmission, functional
status, quality of life, and death.
It is recognized that an episode of AKI is associated
with a high incidence of poor outcomes, some of which
may occur in the rehabilitation phase following recovery
from the acute illness. There are limited data published
on the longer term outcomes of AKI survivors in the
developed world and even less information on those in
the developing world. It is therefore proposed that more
data should be collected on patient outcomes following
AKI to enable the identiﬁcation of speciﬁc risk factors for
this patient population. This in turn may allow the
development new therapeutic interventions.
Based on our current understanding, patients in the
developing world are at risk of both renal and nonrenal
sequelae. The renal sequelae include de novo CKD, CKD
progression, ESRD, and further episodes of AKI.11 A
recent meta-analysis demonstrated that AKI survivors
have a 10-fold higher risk of CKD, 3-fold increased risk
of ESRD, and double the risk of death.26 A retrospec-
tive study in India reported that 15% of AKI survivors
were discharged on renal replacement therapy, 12.5%
remained dialysis dependent, and 19% to 31% had
CKD at long-term follow up (1–10 years).22 A system-
atic review of outcomes of AKI in 186 adults and 676
children in Sub-Saharan Africa demonstrated that 13%
of adults and 10% of children had persistence of renal
dysfunction (not requiring dialysis) at the time of583
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ﬁrst few months after the AKI episode.3 Survivors of
AKI therefore represent a vulnerable population that
needs to be reviewed early in an effort to improve
outcomes.
There are many nonrenal sequelae that have been
identiﬁed in patients in the developed world.56 It is
proposed that the nonrenal sequelae to monitor include
hypertension,6 cardiovascular disease,57 all-cause
readmission,58 functional status,59 quality of life,59
and death.26
Special Considerations
There is very little published literature on the longer
term outcomes after AKI in pediatric patients. Many of
these patients will be lost to follow-up, either through
failure to refer after an episode of AKI or at the time of
transition from childhood to adulthood. The outcome
measures should be the same as in adults, but perhaps
modiﬁed to include developmental parameters.
In developing countries, it must be recognized that a
substantial proportion of patients with AKI do not
receive dialysis due to restrictions on health care pro-
vision. Poor outcomes in these countries will reﬂect the
severity of patient illness and delayed presentation to a
nonuniform health care infrastructure.25 Currently in
most countries in Sub-Saharan Africa, access to
specialist nephrology care is dependent on out-of-
pocket payments by patients. There is increasing
pressure across both the developing and developed
worlds to justify where to spend scarce ﬁnancial re-
sources on health care. The collection of more data
describing the vulnerable nature of these patients and
their adverse outcomes will be key. Medical managers
and politicians must be informed of the consequences
of failing to prevent avoidable readmission and pro-
gression of CKD with its cost to society. In many
countries, resources are scarce or restricted with mul-
tiple health care priorities competing for the same pot
of money. It is important to emphasize the nature of
AKI in identifying vulnerable patients with a variety of
health care needs, many of which are not nephrology
centered.
Question 3: What are the components of
patient-centered monitoring after an AKI
episode?
Consensus Statement
 Consensus Statement 3A: All patients with AKI should
have continued access to the health care system.
 Consensus Statement 3B: Low-risk patients
(Figures 2 and 4) should have their kidney function
and proteinuria checked within 3 months of the AKI
episode (per the KDIGO guidelines). Monitoring can584be done by any health care provider or a nephrologist
in an outpatient setting.
 Consensus Statement 3C: High-risk patients (Figures 2
and 4) should preferably be assessed by a nephrolo-
gist within 1 month of the AKI episode. Earlier
follow-up may be necessary to reduce recurrent AKI
and hospital readmission.
 Consensus Statement 3D: Patients who remain dialysis
dependent should be closely monitored by a
nephrologist for renal recovery because renal func-
tion may recover several months after an episode of
AKI.
Patient monitoring after an episode of AKI should
begin as soon as possible. In 2 single-center studies,
less than half of physician discharge summaries docu-
mented the presence of AKI.60,61 A recent United States
Renal Data System report showed that 75% of patients
will see a primary care physician within 3 months of an
AKI episode compared with 13% of patients who will
see a nephrologist.13 However, the proportion of pa-
tients who have their serum creatinine measured
within 3 months of an AKI episode only ranges be-
tween 55% and 70%.13,62,63
In the developing world, 1 study found that
scheduled follow-up for AKI is similar to that in the
developed world.2 However, another study from China
reported a 74% AKI nonrecognition rate.23 This
observation suggests patient follow-up in the devel-
oping world may be much lower than anticipated.
Reasons for a lower follow-up rate in survivors of AKI
may include the policy and ﬁnancial barriers listed
earlier (ﬁnancial constraints, health insurance coverage,
physician availability). These factors limit access to
care, which may be magniﬁed by the cost of diagnosing
and monitoring AKI with expensive serum creatinine
testing.23 Medical barriers may include the silent and
asymptomatic nature of kidney disease and competing
health demands of higher priority (e.g., postsurgical
care), so patients and health care providers may not
emphasize follow-up care after AKI. Therefore,
communication is critical between health care pro-
viders who care for patients during the AKI episode
and health care providers responsible for longitudinal
post-AKI care. Simple quality-improvement initiatives
may help to track patients and facilitate follow-up
care,12,19 but, at the very least, patients with AKI
should be offered continued access to the health care
system.
Currently, there is a lack of evidence to guide the
timing, frequency, and method of evaluation after an
episode of AKI, including what type of health care
provider (e.g., community provider or nephrologist)
should assume primary responsibility for patient
follow-up. Multiple observational studies haveKidney International Reports (2017) 2, 579–593
Figure 4. A potential follow-up pathway for patients after an AKI episode. This pathway shows different recommended strategies for patient
monitoring after an AKI episode. The intensity of monitoring depends on the patient’s risk of adverse events (Figure 2, to be assessed at the
patient’s last point of contact with the health care system) and the results of the initial follow-up visit. Follow-up should also be individualized
(e.g., moderate-risk patients could be treated as low risk or high risk) and dynamic. For example, patients thought to be low risk may require
more frequent, nephrologist-led monitoring if they are found to have evidence of CKD or CVD at their initial post-AKI visit. AKI, acute kidney
injury; CKD, chronic kidney disease; CVD, cardiovascular disease.
SA Silver et al.: Rehabilitation After AKI MEETING REPORTdemonstrated that new-onset and progressive CKD
tends to occur soon after an episode of AKI, with a
median time to CKD of w30 days.3,4 The timing of
microalbuminuria after AKI has not been extensively
studied, but between 40% and 50% of patients had
evidence of microalbuminuria within 3 months in 2
studies19,64; these results are consistent with long-term
follow-up from the Randomized Evaluation of Normal
versus Augmented Levels of Renal Replacement Ther-
apy (RENAL) trial.65 The 90-day time point also ap-
pears to be important for recurrent episodes of AKI.
Among 11,683 AKI hospitalizations, Siew et al.33 found
that the median time to recurrent AKI was 64 days. Of
the 2954 patients (25%) with recurrent AKI, close to
60% of the episodes occurred within the ﬁrst 90 daysKidney International Reports (2017) 2, 579–593after hospital discharge. For nonrenal outcomes, less is
known about the timing of events after AKI to guide
monitoring strategies. Hsu et al.6 demonstrated that
new-onset hypertension was present within 180 days
of hospital discharge, affecting 31% of patients after an
AKI episode. Patients who survive an episode of AKI
are also at higher risk of hospital readmission at 30 days
compared with patients without AKI, primarily due to
heart failure and pulmonary edema.58,66,67 Rates of
all-cause 30-day readmission range between 15%
and 25%, with a median time to readmission of 11
days.66–70
Given this limited evidence on the timing of adverse
outcomes after AKI, we agree with the KDIGO AKI
guidelines that patients should be evaluated within 3585
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should begin at the last point of contact with the health
care system, whether that be a community provider in
an outpatient clinic or a nephrologist during an inpa-
tient hospitalization. We would only delay the ﬁrst
follow-up visit until 3 months for low-risk patients
(Figure 2), given that CKD and recurrent AKI events
tend to occur before 3 months. Follow-up visits for
low-risk patients should consist of at least a serum
creatinine check and proteinuria assessment. Other
considerations for low-risk patients include a brief
history to ensure resolution of the illness responsible
for the AKI episode and a blood pressure check. Such
monitoring can be done by a local health care provider
or a nephrologist in an outpatient setting, including
remotely via telemedicine as local resources permit
(Figure 4).
For higher risk patients (Figure 2), we recommend an
assessment by a nephrologist within 1 month of the AKI
episode. This shorter follow-up period precedes the
onset of CKD and recurrent AKI for most patients, but
may be too delayed to prevent hospital readmissions. A
visit with a nephrologist has been associated with
enhanced survival; Harel et al.15 demonstrated lower
mortality in survivors of dialysis-requiring AKI who
saw a nephrologist relative to propensity score–matched
AKI patients without such follow-up (HR 0.8, 95% CI
0.6–0.9). Although the processes of care responsible for
these improved outcomes remain to be determined, with
prospective studies under way (ClinicalTrials.gov NCT
02483039),12,71 previous research has demonstrated that
nephrologists are more skilled at recognizing and man-
aging CKD complications according to evidence-based
guidelines compared with primary care providers.72,73
Although our preference is for nephrologist-led
follow-up, there is a shortage of nephrologists
throughout much of the developed world.74 In such
cases, it is reasonable for a nonnephrologist physician or
local health care provider to direct the follow-up plan,
with nephrology support via telemedicine, if available.
We cannot be sure that any monitoring strategy will
be effective in mitigating adverse outcomes in the post-
AKI setting. Nonetheless, it seems reasonable to provide
interventions designed to prevent recurrent AKI and
acute illness and recognize CKD. Suchmonitoring should
include a complete history and physical examination
that targets risk factors for AKI and cardiovascular dis-
ease (e.g., an assessment of intravascular volume status).
We recommend that kidney function and proteinuria be
assessed, with other laboratory studies (hemoglobin,
electrolytes, cholesterol, mineral metabolism) ordered
based on the clinical context. More invasive in-
vestigations such as imaging tests (e.g., abdominal ul-
trasound) or a kidney biopsy should not be overlooked,586depending on the etiology of the patient’s AKI and
current level of kidney function (Figure 4).
Patients cannot be followed for an indeﬁnite period
of time after an episode of AKI. We recommend that the
frequency of visits be individualized based on patient
risk for adverse events and results from the initial visit
(Figures 2 and 4). Most reported post-AKI clinics assess
patients every 3 months, but there is no evidence that
this approach modiﬁes outcomes.12,19–21 One year after
the AKI episode, kidney function appears to stabi-
lize.21,75 Therefore, patients could be assessed for
specialized CKD care at this time point. One approach
currently being evaluated is to use the KDIGO CKD
guidelines to triage patients at 1 year35; patients
without CKD or with low-risk CKD are transitioned to
their primary care provider along with an educational
pamphlet on post-AKI care, whereas patients with
moderate- to high-risk CKD are referred for ongoing
specialized nephrology care.12 This approach may help
to ensure adequate resources to schedule follow-up
visits for patients with new-onset AKI within the rec-
ommended time intervals.
One patient population that warrants additional
discussion is patients who still require dialysis for AKI.
Rates of renal recovery among outpatient hemodialysis
patients who started dialysis for AKI are not as un-
common as previously reported.76,77 Despite a high
prevalence of comorbid conditions, Hickson et al.78
found a recovery rate to dialysis independence of
21% at 6 months. Median time to recovery was 8
months, with 94% of recoveries occurring within 6
months. No patients recovered to dialysis indepen-
dence after spending >12 months on dialysis. These
results are consistent with Centers for Medicare and
Medicaid Services data, where recoveries are most
common within 3 months and rare after 12 months.79 In
many lower middle–income countries, dialysis for AKI
is limited to a speciﬁc period of time. If there is no renal
recovery and no plan for kidney transplantation,
dialysis may be stopped unless patients can afford
continued treatment.80 This practice emphasizes the
importance of rehabilitation strategies in AKI patients
on dialysis, especially during the ﬁrst few months of
dialysis when most renal recovery may occur.
Currently, no guidelines exist regarding monitoring
of renal recovery in dialysis patients, and research in
this area is urgently needed. To further complicate
matters, there is no single symptom, sign, or investi-
gation that identiﬁes renal recovery (Table 1). We agree
with the American Society of Nephrology AKI
Advisory Group that monitoring for recovery in
dialysis-dependent patients after AKI requires careful
observation and an individualized approach.81 Symp-
toms suggestive of recovery include muscle cramps,Kidney International Reports (2017) 2, 579–593
Table 1. Indicators of renal recovery in patients with acute kidney injury requiring dialysis
Symptoms Signs Laboratory and drug changes
Muscle cramps Intradialytic hypotension Decrease in predialysis serum creatinine
Light-headedness Decreased interdialytic weight gain Normalization of potassium, phosphate, or parathyroid hormone
Decreased ultraﬁltration on hemodialysis Increased urine output Decreased need for phosphate binders
Decreased need for hypertonic peritoneal ﬂuid Decreased need for erythropoietin
Estimated GFR >15 ml/min per 1.73 m2 (using a 24-hour
urine for urea and creatinine clearance)
GFR, glomerular ﬁltration rate.
SA Silver et al.: Rehabilitation After AKI MEETING REPORTlightheadedness, and lower requirements for ultraﬁl-
tration or hypertonic peritoneal ﬂuid. Although some
patients may develop an improved sense of well-being,
other patients may feel worse because of unnecessary
ﬂuid removal.82 Signs to monitor for include intra-
dialytic hypotension, increasing urine output, and
decreasing interdialytic weight gain.81 Falling serum
creatinine is a well-recognized investigation that in-
dicates renal recovery; however, decreasing serum
creatinine values could also reﬂect catabolism,
decreased muscle mass, or malnutrition. Other labora-
tory changes that may indicate renal recovery include
normalization of serum electrolytes, mineral meta-
bolism (e.g., elimination of phosphate binders), and
hemoglobin (e.g., elimination of erythropoietin ther-
apy). These changes are likely to occur gradually and
may not be apparent without carefully monitoring
patient trends, underscoring the individualized
approach needed to monitor dialysis patients for re-
covery after AKI.81,82
When renal recovery is suspected, the next step is a
24-hour urine for urea and creatinine clearance mea-
surement starting 24 hours before the next dialysis
session during the longest interdialytic interval. Both
creatinine and urea clearance are inaccurate in dialysis
patients, but the direction and magnitude of the
different clearances produce a reasonable estimate of
inulin clearance.83 It has been suggested that a mean
clearance above >15 ml/min per 1.73 m2 warrants a
reduction in dialysis treatment, but this approach has
yet to be validated.82
Until additional data are available, we reinforce the
importance of an individualized approach to moni-
toring patients who are still on dialysis after an episode
of AKI. There are several nuances to caring for these
patients, so a nephrologist may be best equipped for
this role. The entire dialysis unit should also be aware
of the potential for renal recovery in this population to
decrease the health and economic costs from inadver-
tent prolongation of dialysis.Special Considerations
Because the pathogenesis of cardiovascular disease
begins early in childrenwith CKD, prompt identiﬁcationKidney International Reports (2017) 2, 579–593of CKD in the pediatric population is arguably of greater
importance than in adults.84 Earlier follow-up must be
balanced against caregiver stress and competing
specialist appointments because pediatric AKI is most
often a sequelae of other serious illnesses or their treat-
ment. In terms of patient monitoring, the most common
renal sequela in the largest pediatric cohort study was
the presence of persistent microalbuminuria in 10% of
patients.53 An additional consideration is cystatin C as a
marker of kidney function because decreased muscle
mass in children older than 2 years of age renders serum
creatinine a less sensitive measure of kidney function
when used in isolation.85
In our experience, some patients in resource-limited
settings face sociocultural pressures to return to work
soon after their acute illness has resolved. In addition
to the policy, ﬁnancial, and medical factors described
previously, follow-up care pathways in the developing
world need to be individualized, given the high rates of
community-acquired AKI. Follow-up care should be
ﬂexible to both work needs and remote settings,
including telemedicine and point-of-care monitoring
options to ensure that some assessment of kidney
function is performed. Similar to high-income coun-
tries, particular attention is required in lower middle–
income countries to improve the process of care for
patients who still require dialysis after AKI. A sizable
portion of these patients recover kidney function up to
1 year after the AKI episode, so they should not arbi-
trarily be labeled and treated as ESRD patients.
Question 4: What management strategies are
recommended after an AKI episode?
Consensus Statement
 Consensus Statement 4A: Patients should continue to
receive treatment tailored to the etiology of their AKI
to promote renal recovery.
 Consensus Statement 4B: After an AKI episode, all
patients should receive counseling on lifestyle
changes and dietary modiﬁcation.
 Consensus Statement 4C: Patients should receive
comprehensive medication reconciliation and cardio-
vascular risk reduction appropriate to their clinical
circumstances.587
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dependent should have their dialysis regimens
individualized.
Patients recovering from AKI often have underlying
diseases that require ongoing drug therapy. These
conditions may be primarily renal (e.g., acute intersti-
tial nephritis, Goodpasture syndrome) or nonrenal
(e.g., lupus, myeloma). These diseases may still be
treated with steroids and immunosuppressant/cyto-
toxic drugs based on the clinical context to promote
renal recovery. The dosage of immunosuppressant/
cytotoxic drugs may need to be adjusted for renal
function.
To maintain renal and cardiovascular health, pa-
tients should receive basic counseling on lifestyle and
dietary modiﬁcations. Key areas include maintaining
adequate hydration and increasing ﬂuid intake during
episodes of diarrhea/vomiting, which are common in
tropical countries. Additional ﬂuid balance assessments
and diuretic adjustments may also be needed for pa-
tients with heart failure.
In terms of pharmacologic management, patients
may have underlying conditions such as heart failure
that require speciﬁc treatment with medications (e.g.,
angiotensin-converting enzyme inhibitors [ACEIs] or
angiotensin receptor blockers [ARBs]). The well-
recognized increase in serum creatinine with ACEIs/
ARBs means that these drugs are usually discontinued
in patients with AKI. However, there is compelling
evidence that these drugs are associated with reno-
protection in patients with proteinuria and diabetic
and nondiabetic CKD and patients with systolic
dysfunction.35 The safety of these drugs in the imme-
diate post-AKI period is not known. In 1 study using
administrative databases, patients with an acute coro-
nary syndrome in whom post-contrast AKI developed
were signiﬁcantly less likely to be started on ACEIs/
ARBs, and patients with KDIGO stages 2 and 3 AKI
were less likely to be started on beta-blockers and
statins compared with non-AKI patients. On follow-up,
the use of each of these cardioprotective medications
was associated with a lower risk of cardiovascular
mortality.86 These beneﬁts were found across all cate-
gories of patients, including those with preexisting
CKD, diabetes, heart failure, and proteinuria. In
another study, 142 of 1463 subjects with AKI (9.7%)
were treated with an ACEI. There was no associated
reduction in mortality after full adjustment for
covariates.87
Beta-blockers are not associated with an increased
risk of the development of AKI, and there is no a priori
reason not to restart them post-AKI if needed. The
potential for statins to increase the risk of AKI due to
rhabdomyolysis is well recognized.88 In subjects who588experience AKI due to another cause, however, there
seems to be no reason to discontinue statins during or
after an episode of AKI. More studies are required to
establish the optimal timing of reintroduction of
ACEIs/ARBs post-AKI. However, there is no reason to
stop these and other cardiovascular medications
indeﬁnitely in all patients after an episode of AKI.
Decisions should be individualized, especially because
the risk of AKI due to cardiovascular medication
appears to be small compared with the risk of AKI due
to preexisting patient characteristics.89,90
Other medication classes should be avoided if
possible, which emphasizes the importance of medica-
tion reconciliation after AKI. In 1 study, 19% of sur-
vivors of AKI used nonsteroidal anti-inﬂammatory
drugs, which are potentially nephrotoxic.91 The use of
other nephrotoxic agents, such as aminoglycosides and
radiocontrast media, should also be restricted in
patients after AKI unless there is a compelling need.
The management of patients still requiring dialysis
after AKI is particularly challenging without
evidence-based guidelines. Important issues include
prevention of intradialytic hypotension, determina-
tion of ﬂuid removal targets, and medication
adjustments for renal function. In addition, patients
recovering from AKI are likely to be anemic.
Although erythropoietin treatment does not prevent
further injury or reduce the risk of recurrent AKI,
such treatment is safe and should be offered to
anemic patients (dialysis dependent or independent)
in the recovery phase of AKI based on established
targets for patients with CKD.92,93 Similar to moni-
toring strategies for dialysis patients post-AKI, we
agree with the American Society of Nephrology AKI
Advisory Group that the management of dialysis-
dependent patients after AKI requires an individu-
alized approach.81,94Special Considerations
We are unaware of any studies on post-AKI manage-
ment in children. It seems reasonable to apply many of
these principles in adults to the pediatric population,
including treatment of the cause of AKI (e.g.,
hemolytic-uremic syndrome), counseling to avoid
dehydration, and medication reconciliation.
In developing countries, important considerations
involve medication adjustments and reconciliation.
Patients may be taking indigenous or allopathic ther-
apies, which will need to be carefully reviewed for
nephrotoxicity. Specialized pharmacist expertise is also
not always available, so health care providers may need
to rely on published resources to assist with drug
dosing and therapeutic drug monitoring.95Kidney International Reports (2017) 2, 579–593
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recommended after an AKI episode?
Consensus Statement
 Consensus Statement 5A: After an episode of AKI,
patients, their caregivers, and their health care pro-
viders should be made aware of the AKI diagnosis.
AKI should also be documented in the patient’s
medical record to increase its recognition as a health
issue.
 Consensus Statement 5B: All patients, their caregivers,
and their health care providers should receive in-
formation on the etiology of the AKI episode, patient
risk proﬁle, and the importance of follow-up,
including steps to monitor, manage, and prevent
future AKI episodes.
 Consensus Statement 5C: We recommend standardized
strategies to communicate and educate patients,
caregivers, and health care providers. Education
should begin early on after AKI diagnosis and
continue throughout follow-up.
It is recommended that education should be focused
on a patient-centered approach, which is often not the
case.14 The importance of kidney health should be
emphasized throughout developed and developing
countries to allow providers to deliver the appropriate
follow-up care in a more systematic manner. Patients
should be encouraged to become active partners in their
own health management. It would be expected that pa-
tient follow-up rates may improve by empowering them
with knowledge concerning their own health and future
risks. Currently, very few patients are aware that they
have had an episode of AKI, let alone that they are at an
increased risk of long-term adverse outcomes.96 Going
forward, this is a situation that must change.
There have been no formal studies onwhen to educate
patients after an episode of AKI. It would therefore seem
prudent to provide information to the patient shortly
after the diagnosis of AKI and provide an opportunity
for the patient and other family members to discuss
immediate management as well as longer term care.
There is also very little published literature
describing what information is routinely given to pa-
tients after an episode of AKI. Patient education should
include information on maintaining good hydration
and avoiding nephrotoxins. There have been some re-
ports of patients provided with “sick day” guidance,
which promotes self-care with respect to holding
medications at the time of illness (e.g., during episodes
of dehydration).12 However, tailoring such initiatives
for patients with multiple conditions can be complex.97
Lunyera et al.98 administered an 18-item Web-based
questionnaire to physicians actively engaged in
providing nephrology care in developing countries.Kidney International Reports (2017) 2, 579–593This identiﬁed a lack of meaningful and targeted
approaches to education with a reliance on interna-
tional guidelines rather than local guidelines tailored
for particular patient populations. Evans et al.99 iden-
tiﬁed the deﬁciencies in the management of AKI among
Malawian health care workers. One hundred delegates
attended a course on AKI in Malawi. At this workshop,
32% of all health care workers had never received
training in any aspect of renal disease, and 50% had
never received training in AKI, even though 69% had
managed patients with AKI. This lack of awareness is
multifactorial with a high turnover of staff making this
task an ongoing challenge. A lack of knowledge on the
current deﬁnitions of AKI and when to refer were
reported in the United Kingdom recently.100 Evidence
that an education package could improve patient out-
comes as part of a quality improvement program was
provided by Xu et al.101 in 2 large teaching hospitals in
the UK. The “Think Kidneys” program (www.
thinkkidneys.nhs.uk)102 in the United Kingdom has
developed a range of educational resources for both
primary and secondary care that are freely available.
Special Considerations
It has been reported that parents/guardians of children
who have recovered from an episode of AKI are espe-
cially interested in the recovery process and preser-
vation of their child’s kidney function. Initiatives
include the use of information distributed on laminated
wallet cards; this provides a handy reference on
nephrotoxic medications and contact information for
additional questions.12
The delivery of education on AKI to health care
workers from developed countries must be tailored to
meet the needs of the learners. Local, regional, or na-
tional events supported by experts in the ﬁeld provide
an opportunity to raise awareness among a large
number of health care professionals but can prove
difﬁcult to attend. The development of electronic AKI
learning modules as part of a coordinated program of
education with credits attached should be explored as a
way to reach a larger audience. Such modules should
include all phases of AKI care and propose improve-
ments in the rehabilitation phase of AKI.103
Research Questions
 When is further recovery of kidney function unlikely
after an episode of AKI? How do patient, kidney
disease, and process of care factors affect the likeli-
hood of kidney recovery?
 Can a simple and practical risk equation be developed
to predict adverse events after an AKI episode?
 In what proportion of patients who survive an AKI
episode do adverse events develop over the short589
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 Does follow-up with a health care provider after an
episode of AKI improve outcomes in lower middle–
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Survivors of AKI represent a high-risk group, and we
have summarized several opportunities to improve
their long-term outcomes in the developing world.
While the evidence base matures, an episode of AKI
should be viewed as a serious health event with
downstream consequences that have renal and non-
renal sequelae. Our recommendations urge health care
providers to consider intensive follow-up for every
patient who survives an episode of AKI, especially
patients with preexisting CKD and patients who
remain dialysis dependent at hospital discharge.
Simple interventions such as lifestyle changes, medi-
cation reconciliation, blood pressure control, and ed-
ucation could have signiﬁcant population-level
effects, and promoting renal recovery in a small
number of patients with dialysis-dependent AKI
could have signiﬁcant cost savings. More research is
clearly needed to identify the highest risk patients
with AKI and to determine the components of
evidence-based rehabilitation after AKI. However,
AKI is a global public health problem that affects 13.3
million people per year,2 continuing the status quo,
and hoping for different results no longer seems like a
reasonable option. We hope that the consensus state-
ments developed in this review help to provide cli-
nicians with guidance on the care of patients after an
episode of AKI and serve as a road map for future
research efforts.590DISCLOSURE
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